Search results
Showing 1576 to 1590 of 2581 results for methods
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.
Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.
retaining capacity, may need support to make a decision.High-quality mixed methods studies with a controlled effectiveness component...
nature of delirium and its consequences makes it important to establish all methods of prevention. Pharmacological agents may be a...
Learning disabilities and behaviour that challenges: service design and delivery (NG93)
This guideline covers services for children, young people and adults with a learning disability (or autism and a learning disability) and behaviour that challenges. It aims to promote a lifelong approach to supporting people and their families and carers, focusing on prevention and early intervention and minimising inpatient admissions.
This guideline covers needle and syringe programmes for people (including those under 16) who inject drugs. The main aim is to reduce the transmission of viruses and other infections caused by sharing injecting equipment, such as HIV, hepatitis B and C. In turn, this will reduce the prevalence of blood-borne viruses and bacterial infections, so benefiting wider society.
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)
NICE has developed a medtech innovation briefing (MIB) on Serve-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children .
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
NICE has developed a medtech innovation briefing (MIB) on the Secca System for faecal incontinence
Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)
Evidence-based recommendations on rituximab for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on vinflunine (Javlor) for treating advanced transitional cell carcinoma of the urothelial tract in adults.
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.
UrgoStart for treating diabetic foot ulcers and leg ulcers (HTG502)
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .